Affiliation:
1. Federal State Budgetary Educational Institution of Higher Education «Samara State Medical University»
of the Ministry of Healthcare of the Russian Federation
Abstract
Dabigatran is highly effective oral anticoagulant used in patients with atrial fibrillation, venous thrombosis, pulmonary embolism, orthopedic surgery. The most important role in activation and transport of dabigatran play hepatic carboxylesterase-1 (CES-1) and P-glycoprotein. To date were studied different polymorphisms that affect the pharmacokinetics of dabigatran such as rs2244613 (C > A), rs8192935 (T > C) и rs71647871 (G > A), rs1128503 (1236 C > T), rs2032582 (2677 G > T), rs1045642 (3435 C > T) и rs4148738 (G > A) and others. At the same time, there is no need of dabigatran pharmacogenetics testing in routine care. On the other side, existing literature data is often controversial, that’s why future studies are needed to answer the above-mentioned question.
Publisher
Institute of Cardio Technics - INCART
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Emergency Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献